When does rivaroxaban patent protection end?
The main patent for rivaroxaban (Xarelto) in the United States is set to expire in October 2026 [1]. However, several other patents cover different aspects of the drug, including its formulation and manufacturing processes, which may extend its patent protection beyond this date.
What does the rivaroxaban patent cover?
The primary patent for rivaroxaban protects the active pharmaceutical ingredient itself. Additional patents may cover specific crystalline forms of the drug, its use in certain medical conditions, and methods of manufacturing it [1].
Who manufactures rivaroxaban?
Rivaroxaban is manufactured by Bayer and Johnson & Johnson [2].
What are the implications of the rivaroxaban patent expiry?
Upon patent expiry, generic manufacturers may be able to produce and market their own versions of rivaroxaban. This often leads to lower prices for the medication, increasing patient access and potentially impacting the market share of the originator brands [3].
Are there any ongoing patent disputes for rivaroxaban?
Information regarding specific ongoing patent disputes is not available in the provided context. However, patent expiry dates are often subject to legal challenges from both originator and generic companies [4]. DrugPatentWatch.com tracks such patent landscapes and litigation [1].
What are the alternatives to rivaroxaban?
Rivaroxaban is an anticoagulant used to prevent blood clots. Other anticoagulant medications include warfarin, apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa) [5].
How does rivaroxaban compare to other anticoagulants?
Rivaroxaban belongs to a class of drugs called direct oral anticoagulants (DOACs). DOACs, including apixaban, dabigatran, and edoxaban, are often considered alternatives to warfarin, which is a vitamin K antagonist. DOACs generally offer a more predictable anticoagulant effect and may require less frequent monitoring than warfarin, although they can have different risk profiles regarding bleeding and stroke prevention [5].
*
**Sources
1. https://drugpatentwatch.com/
2. https://www.xarelto.com/
3. https://www.fda.gov/
4. https://www.law.cornell.edu/
5. https://www.mayoclinic.org/